These are my notes from the meeting, not in any particular order.

General

About 30-40 people in attendance, about 10 of them from Resverlogix, including Don, Norman Wong, Brad and Sarah.

Business Portion

Meeting got underway at 9:00. Two resolutions passed as expected. I think 98.7% in favor of the first and 97.9% for the second. This wrapped up at about 9:15.

Q&A

Resverlogix still in active discussions with FDA for the Phase III trial in US. Just takes a while to get everything done. Still positive on everything moving ahead, although I got the impression we might see things moving forward in China and Europe a bit more quickly.

Looking at moving to a different department at FDA to make things move faster, so instead of endocrin and metabolic, it might be cardio and renal, which has slightly different requirements (I could have this wrong)

Believes there will be announcements regarding orphan indications in the next 3 months, hopefully before the AGM in Septembe.r

Funding for Alzheimer studies is likely a no go for this year but will likely be reapplying for funding for 2016.

Gave the indication that staff were swamped with work right now, including lots around getting the trial finalized and Brad fielding calls from "interested" parties.

A bit of change in plans around the trial. Will now include both atorvastatin and rosuvastatin users so that they can get further understandings on why it works well with one and not the other. Anywhere from 2400-4800 patients, dosing up to 2 yrs with average of 18 months. 250 of those likely in China territories with funding provided by Shenzen.

They basically want to run only 1 Phase III trial instead of FDA coming back and asking why lipitor users don't benefit as much and making them do another IIb.

NASDAQ listing still on the radar with possible discussion at next board meeting. Still nothing definite but I got the impression they weren't happy with small # of shares traded on TSX. A company with this potential should be doing a lot more.

Very happy with the things they're learning from their blood bank -- nobody else is even close. Feel there is a huge potential for follow on compounds down the road as they understand more.

Looking for other ways of continuing company growth including deals with right of first refusal. Did not want to dilute too much more if at all possible.

Expects that some additional analyst reports will be published in the near future

Still believes that company is 8 years ahead of competitors in this space and lead is increasing daily. They have a top notch team who are very excited and proud of the work they are doing.

Session concluded around 9:45

My thoughts

For those of you who get down from time to time as the stock price is slowly trending down, take comfort in the fact that this company has a lot of good things going on. When the industry finally understands the positive benefits that are being discovered, I believe it will be the blockbuster that we are all expecting.

GLTA

masila